Follow us on:

For more than 30 years, European market has been a priority for Indian pharmaceutical generic manufacturers. Aurobindo, Dr Reddys or...

Non-European pharmaceutical companies that choose to enter European markets plead different reasons to do so: access to a developed...

According to the results of the Emergpharma 2018 panel, top pharmaceutical companies still have a lot of work to do in emerging markets....

German generics market is the biggest in Europe in terms of values and units. It is also one of the most dynamic and with the largest...

A sub-study from the report “German generics market 2016-2018” recently published by Emergpharma shows interesting facts regarding the...

Preliminary results of the First Report on the German market of oncological medicines 2016-2018 performed by Emergpharma show some...

Mabthera (rituximab) has faced the launch of first biosimilars in EU markets between 2016 and 2018. Some outcomes from Emergpharma's...

Twelve years after the launch of the first biosimilar in Europe, there are still limited data available on the medium-term impact of the...

The available data on biosimilars in Europe are still insufficient to carry out a rigorous analysis to show correlations. However, given...

Biosimilars have traditionally been seen by large pharmaceutical companies as a threat to their most profitable products and the priority...

Recently we were hired by a pharmaceutical company with headquarters in an Asian country that had decided to expand to European markets....

Healthcare companies, mostly small and medium-size, are making relevant errors that seriously compromise their chances of success in new...

Conclusions of a survey on biosimilar adoption in the EU Top 5 A few weeks ago I published an article in Biosimilar Development on the...

Preliminary results of the Emergpharma’s “biosimilar 255 tracking January 2020” Emergpharma has just completed the first phase of its...

We are witnessing the collapse of the units of intensive care in hospitals. The coronavirus crisis, that apparently "nobody saw coming"...

"After reviewing the existing literature on possible therapeutic options; treating patients with severe or critical Covid-19-induced...

In previous articles, I have shown some ideas about the past, present, and future of biosimilars. Once again, I would like to insist on...

As we insist on almost all our articles, biosimilars are not an option, but a need. As commented in our presentation last Thursday at...

Risks associated with the decision to develop biosimilars As we have seen in recent years, many companies that have developed or...

A few days ago, Biopharmalinks (Emergpharma, www.emergpharmalinks.com) finished the first part of its ambitious research on biosimilars...